|Bid||1.0500 x 1800|
|Ask||1.0600 x 1800|
|Day's Range||1.0300 - 1.0800|
|52 Week Range||0.9210 - 29.2500|
|Beta (5Y Monthly)||2.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Inpixon (Nasdaq: INPX), the Indoor Intelligence™ company, today announced the release of its latest indoor mapping platform, Inpixon Mapping 4.14. This release introduces a new customer administration tool, SDK-based dynamic wayfinding, additional tools for developers, and more.
Inpixon (Nasdaq: INPX), the Indoor Intelligence™ company, today announced that it has entered into a securities purchase agreement with an accredited institutional investor to purchase 8,000,000 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 8,000,000 shares of common stock at a purchase price of $1.25 per share (or $1.249 per prefunded warrant) and accompanying warrant in a registered direct offering with a single institutional investor priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.25 per share, are exercisable immediately, and will expire five years following the date of issuance.
Inpixon (Nasdaq: INPX), the Indoor Intelligence™ company, today announced that Inpixon Mapping has been selected by one of the world's premier pharmaceutical companies to provide the visualization required for tracking its critical COVID-19 vaccine-related assets. Inpixon Mapping is currently contracted for deployment in multiple facilities utilized by this company, which specializes in the development of medicines and vaccines across a wide range of disciplines, and multiple additional locations are anticipated to be added over the coming weeks and months.